Abstract

You have accessJournal of UrologyProstate Cancer: Localized III1 Apr 2014MP45-17 SIGNIFICANT ASSOCIATION BETWEEN ABO BLOOD GROUP AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY Yoshio Ohno, Makoto Ohori, Jun Nakashima, Hidenori Okubo, Yoshihiro Nakagami, Takeshi Hashimoto, Takeshi Kashima, Riu Hamada, Kunihiko Yoshioka, and Masaaki Tachibana Yoshio OhnoYoshio Ohno More articles by this author , Makoto OhoriMakoto Ohori More articles by this author , Jun NakashimaJun Nakashima More articles by this author , Hidenori OkuboHidenori Okubo More articles by this author , Yoshihiro NakagamiYoshihiro Nakagami More articles by this author , Takeshi HashimotoTakeshi Hashimoto More articles by this author , Takeshi KashimaTakeshi Kashima More articles by this author , Riu HamadaRiu Hamada More articles by this author , Kunihiko YoshiokaKunihiko Yoshioka More articles by this author , and Masaaki TachibanaMasaaki Tachibana More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1214AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Recent studies have demonstrated associations among the ABO blood group, risk, and prognosis in various diseases. However, to date, few studies have investigated the prognostic significance of the ABO blood group in prostate cancer. The aim of this study was to investigate the association of the ABO blood group with biochemical recurrence (BCR) after radical prostatectomy (RP). Methods We reviewed 719 patients who underwent RP for clinical T1–3N0M0 prostate cancer at our institution between 2000 and 2010. Patients who had neoadjuvant and/or adjuvant therapy were excluded from this study. As a result, a total of 592 patients were included for analysis in the present study. The associations among the ABO blood group, clinicopathologic factors, and BCR were analyzed using univariate and multivariate analyses. Results With a mean follow-up period of 67.3 months, 183 patients (30.9%) experienced BCR, with a 5-year BCR-free rate of 66.1%. Among the clinicopathologic characteristics, only surgical margin status was observed to significantly differ between patients with different ABO blood groups (A vs. B, P = 0.005; AB vs. B, P = 0.007). In univariate analyses, a higher serum prostate-specific antigen (PSA) level at diagnosis, extracapsular extension, a positive surgical margin, seminal vesicle invasion, lymphovascular invasion, and a higher Gleason score (GS ≥8) in the RP specimen were significantly associated with BCR. Although not a significant factor in univariate analysis (P = 0.131), the ABO blood group, in addition to the serum PSA level, extracapuslar extension, positive surgical margin, seminal vesicle invasion, and Gleason score, was an independent predictor of BCR in multivariate analysis. Hazard ratio and 95% confidence intervals for BCR according to the ABO blood group were shown in the Figure. Blood type O patients demonstrated a significantly lower risk of BCR than type A patients (HR, 0.624; 95%CI, 0.432–8211;0.901; P = 0.012). Conclusions The ABO blood group was significantly associated with BCR in prostate cancer patients who underwent RP. In particular, blood type O is significantly associated with a decreased risk of BCR after RP. Further studies are needed to clarify the nature of this association. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e466 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Yoshio Ohno More articles by this author Makoto Ohori More articles by this author Jun Nakashima More articles by this author Hidenori Okubo More articles by this author Yoshihiro Nakagami More articles by this author Takeshi Hashimoto More articles by this author Takeshi Kashima More articles by this author Riu Hamada More articles by this author Kunihiko Yoshioka More articles by this author Masaaki Tachibana More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call